These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35031147)

  • 1. Performance and usability evaluation of novel intradermal injection device Immucise™ and reanalysis of intradermal administration trials of influenza vaccine for the elderly.
    Shimizu S; Tanaka R; Itoh E; Maekawa-Matsuura M; Iwase Y
    Vaccine; 2022 Feb; 40(6):873-879. PubMed ID: 35031147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior immunogenicity profile of the new intradermal influenza vaccine compared to the standard subcutaneous vaccine in subjects 65 years and older: A randomized controlled phase III study.
    Arakane R; Annaka R; Takahama A; Ishida K; Yoshiike M; Nakayama T; Takeshita F
    Vaccine; 2015 Nov; 33(48):6650-8. PubMed ID: 26519549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing Immunogenicity of Influenza Vaccine in the Elderly through Intradermal Vaccination: A Literature Analysis.
    Quach HQ; Kennedy RB
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36366536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.
    Frenck RW; Belshe R; Brady RC; Winokur PL; Campbell JD; Treanor J; Hay CM; Dekker CL; Walter EB; Cate TR; Edwards KM; Hill H; Wolff M; Leduc T; Tornieporth N
    Vaccine; 2011 Aug; 29(34):5666-74. PubMed ID: 21699951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of the new intradermal influenza vaccine in adults and elderly: A randomized phase 1/2 clinical trial.
    Arakane R; Nakatani H; Fujisaki E; Takahama A; Ishida K; Yoshiike M; Nakayama T; Takeshita F
    Vaccine; 2015 Nov; 33(46):6340-50. PubMed ID: 26431983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of an influenza vaccination program offering intramuscular and intradermal vaccines versus intramuscular vaccine alone for elderly.
    Leung MK; You JH
    Vaccine; 2016 May; 34(22):2469-76. PubMed ID: 27079928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
    Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
    Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly.
    Levin Y; Kochba E; Shukarev G; Rusch S; Herrera-Taracena G; van Damme P
    Vaccine; 2016 Oct; 34(44):5262-5272. PubMed ID: 27667332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of intradermal delivery of hepatitis B booster vaccine using the novel drug delivery device VAX-ID™.
    Van Mulder TJS; Withanage K; Beyers KCL; Vankerckhoven VVJ; Theeten H; Van Damme P
    Vaccine; 2019 Jan; 37(4):581-586. PubMed ID: 30587432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
    Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
    Hung IF; Zhang AJ; To KK; Chan JF; Li P; Wong TL; Zhang R; Chan TC; Chan BC; Wai HH; Chan LW; Fong HP; Hui RK; Kong KL; Leung AC; Ngan AH; Tsang LW; Yeung AP; Yiu GC; Yung W; Lau JY; Chen H; Chan KH; Yuen KY
    Lancet Infect Dis; 2016 Feb; 16(2):209-18. PubMed ID: 26559482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic.
    Chuaychoo B; Kositanont U; Rittayamai N; Niyomthong P; Songserm T; Maranetra KN; Rattanasaengloet K; Nana A
    Hum Vaccin Immunother; 2016 Jul; 12(7):1728-37. PubMed ID: 27153158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand.
    Garg S; Thongcharoen P; Praphasiri P; Chitwarakorn A; Sathirapanya P; Fernandez S; Rungrojcharoenkit K; Chonwattana W; Mock PA; Sukwicha W; Katz JM; Widdowson MA; Curlin ME; Gibbons RV; Holtz TH; Dawood FS; Olsen SJ
    Clin Infect Dis; 2016 Feb; 62(3):383-391. PubMed ID: 26486702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.
    Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli C; Groth N; Levin Y; Del Giudice G
    Hum Vaccin Immunother; 2014; 10(6):1701-10. PubMed ID: 24732325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain.
    Hung IF; Levin Y; To KK; Chan KH; Zhang AJ; Li P; Li C; Xu T; Wong TY; Yuen KY
    Vaccine; 2012 Oct; 30(45):6427-35. PubMed ID: 22910287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose sparing with intradermal injection of influenza vaccine.
    Kenney RT; Frech SA; Muenz LR; Villar CP; Glenn GM
    N Engl J Med; 2004 Nov; 351(22):2295-301. PubMed ID: 15525714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody responses after dose-sparing intradermal influenza vaccination.
    Auewarakul P; Kositanont U; Sornsathapornkul P; Tothong P; Kanyok R; Thongcharoen P
    Vaccine; 2007 Jan; 25(4):659-63. PubMed ID: 17011678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of immunogenicity between intradermal and intramuscular injections of repeated annual identical influenza virus strains post-pandemic (2011-2012) in COPD patients.
    Chuaychoo B; Kositanont U; Niyomthong P; Rittayamai N; Srisuma S; Rattanasaengloet K; Wongsrisakunkaew W; Thongam J; Songserm T
    Hum Vaccin Immunother; 2020 Jun; 16(6):1371-1379. PubMed ID: 31770051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity, safety and tolerability of intradermal influenza vaccines.
    Hung IFN; Yuen KY
    Hum Vaccin Immunother; 2018 Mar; 14(3):565-570. PubMed ID: 28604266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.
    Gorse GJ; Falsey AR; Johnson CM; Morrison D; Fried DL; Ervin JE; Greenberg DP; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2013 Dec; 31(50):6034-40. PubMed ID: 24055306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.